CoChat

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Open access
Bhatia, Vipul, Kamat, Nikhil V., Pariva, Tiffany E., Wu, Li-Ting, Tsao, Annabelle, Sasaki, Koichi, Sun, Huiyun, Javier, Gerardo, Nutt, Sam, Coleman, Ilsa, Hitchcock, Lauren, Zhang, Ailin, Rudoy, Dmytro, Gulati, Roman, Patel, Radhika A., Roudier, Martine P., True, Lawrence D., Srivastava, Shivani, Morrissey, Colm M., Haffner, Michael C., Nelson, Peter S., Priceman, Saul J., Ishihara, Jun, Lee, John K. · 2023 · Nature Communications
Cited by 131

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic prostate cancers and the development of a STEAP1-directed chimeric antigen receptor (CAR) T cell therapy. STEAP1 CAR T cells demonstrate reactivity in low antigen density, antitumor activity across metastatic prostate cancer models, and safety in a human STEAP1 knock-in mouse model. STEAP1 antigen escape is a recurrent mechanism of treatment resistance and is associated with diminished tumor antigen processing and presentation. The application of tumor-localized interleukin-12 (IL-12) therapy in the form of a collagen binding domain (CBD)-IL-12 fusion protein combined with STEAP1 CAR T cell therapy enhances antitumor efficacy by remodeling the immunologically cold tumor microenvironment of prostate cancer and combating STEAP1 antigen escape through the engagement of host immunity and epitope spreading.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-37874-2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 131

Metadata

Authors
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L.-T., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, S., Coleman, I., Hitchcock, L., Zhang, A., Rudoy, D., Gulati, R., Patel, R. A., Roudier, M. P., True, L. D., Srivastava, S., Morrissey, C. M., Haffner, M. C., Nelson, P. S., Priceman, S. J., Ishihara, J., & Lee, J. K.
Venue
Nature Communications
Published
2023-04-11
Volume
14
Issue
1
Pages
2041-2041
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4364378852
Cited by
131
References
19
FWCI
13.56
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. https://app.cochat.ai/papers/10.1038/s41467-023-37874-2
The paper
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L.-T., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, S., Coleman, I., Hitchcock, L., Zhang, A., Rudoy, D., Gulati, R., Patel, R. A., Roudier, M. P., True, L. D., Srivastava, S., Morrissey, C. M., . . . Lee, J. K. (2023). Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nature Communications. https://doi.org/10.1038/s41467-023-37874-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.